Cite as: 566 U. S. ____ (2012)

1

SOTOMAYOR, J., concurring

SUPREME COURT OF THE UNITED STATES
_________________

No. 10–844
_________________

CARACO PHARMACEUTICAL LABORATORIES, LTD.,
ET AL., PETITIONERS v. NOVO NORDISK A/S ET AL.
ON WRIT OF CERTIORARI TO THE UNITED STATES COURT OF
APPEALS FOR THE FEDERAL CIRCUIT
[April 17, 2012]

JUSTICE SOTOMAYOR, concurring.
The Court today interprets the counterclaim set forth in
21 U. S. C. §355(j)(5)(C)(ii)(I) to permit generic manufacturers to force brand manufacturers to “correct” inaccurate
use codes. While I too find the counterclaim not “free of
ambiguity,” ante, at 10, I join the Court’s opinion because
I agree this is the most sensible reading in light of the
existing regulatory scheme. I write separately to add the
following observations.
I
I first underscore that the counterclaim can only lessen
the difficulties created by an overly broad use code; it
cannot fix them. The statutory scheme is designed to
speed the introduction of low-cost generic drugs to market.
See ante, at 2 (citing Eli Lilly & Co. v. Medtronic, Inc., 496
U. S. 661, 676 (1990)). To that end, the statute provides
for the rapid approval of a drug that a generic manufacturer seeks to market for unpatented methods of use. The
manufacturer need only submit an abbreviated new drug
application (ANDA) with a section viii statement and a
proposed label that “carves out” from the brand manufacturer’s label any patented methods of use. See ante, at 4.
So long as the use code is not overly broad (and all else is
in order), FDA may approve the application without re-

